Ocugen (OCGN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.06
- Estimate
- -$0.05
- Surprise
- -16.9%
- Revenue (period 2026-06-30)
- $1.5M
- Score today
- 4.7/10
Revenue source: xbrl.
How the report landed
Ocugen (OCGN) reported diluted EPS of -$0.06, in line with the -$0.05 estimate.
Where TrendMatrix's rating stands now
TrendMatrix currently rates OCGN Sell at 4.7/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate; this quarter's -16.9% surprise compares with a -14.8% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: product candidates
- DATA_ISSUE: analyst_target_implausible (raw $12.17 vs price $1.36 — ratio 8.9×). Rejected, falling back to technical TP.
- Quality below floor (1.5 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $1.35
- Price target
- $1.46
- Stop
- $1.26
- Upside to target
- +8.1%
Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.
OCGN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $461.2M
- P/E (fwd)
- -5.1
- 52-week range
- $1.01–$2.73
- Off 52-week high
- 50.5%
- RSI (14)
- 48
- Volume vs avg
- 1.07×
- Score today
- 4.7/10